CIK 0001211583 · Non-accelerated filer<br>Smaller reporting company
FENNEC PHARMACEUTICALS INC.
Sign in to watch- Ticker
- FENC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (919) 636-4530
- Business address
- PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
- Former names
- ADHEREX TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,310,718
- in 4 filings, $1.2M under 10b5-1 plans
Net −$1,310,718. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-31 | Cioffi Christiana Marie Chief Strategy Officer | Grant or award | +156 | 24,644 | ||
| 2026-08-31 | Sayad Pierre Sargis Chief Medical Officer | Grant or award | +168 | 21,519 | ||
| 2026-08-31 | Sayad Pierre Sargis Chief Medical Officer | Sale | −12,000 | $12.18 | $146K | 9,519 |
| 2026-08-31 | Evans Terry L Chief Commercial Officer | Grant or award | +168 | 21,519 | ||
| 2026-08-31 | Hackman Jeffrey S. Chief Executive Officer | Grant or award | +1,159 | 66,302 | ||
| 2026-08-31 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,703 | 241,306 | ||
| 2026-08-28 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +21,928 | $5.10 | $112K | 239,603 |
| 2026-08-28 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise · Stock Options 10b5-1 | −21,928 | 779,330 | ||
| 2026-08-27 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −75,000 | $11.78 | $884K | 217,675 |
| 2026-08-03 | Raykov Rosty Former Director | Sale 10b5-1 | −10,000 | $9.58 | $96K | 131,633 |
| 2026-07-31 | Cioffi Christiana Marie Chief Strategy Officer | Grant or award | +156 | 24,488 | ||
| 2026-07-31 | Sayad Pierre Sargis Chief Medical Officer | Grant or award | +168 | 21,351 | ||
| 2026-07-31 | Evans Terry L Chief Commercial Officer | Grant or award | +168 | 21,351 | ||
| 2026-07-31 | Hackman Jeffrey S. Chief Executive Officer | Grant or award | +1,159 | 65,143 | ||
| 2026-07-31 | Raykov Rosty Former Director | Grant or award | +2,778 | 141,633 | ||
| 2026-07-31 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,703 | 292,675 | ||
| 2026-07-01 | Raykov Rosty Former Director | Grant or award 10b5-1 | +2,778 | 132,857 | ||
| 2026-07-01 | Raykov Rosty Former Director | Option exercise 10b5-1 | +15,597 | $2.45 | $38K | 148,454 |
| 2026-07-01 | Raykov Rosty Former Director | Sale 10b5-1 | −9,599 | $10.41 | $100K | 138,855 |
| 2026-07-01 | Raykov Rosty Former Director | Option exercise · Stock Options 10b5-1 | −15,597 | $2.45 | $38K | 1,525,000 |
Page 2 of 8 · 159 trades